UNITY BIOTECHNOLOGY, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.53 USD | -4.38% |
|
-4.97% | -20.73% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 25.68M |
|---|---|---|---|---|---|
| Net income 2024 * | -38M | Net income 2025 * | -41M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 8.44M | Net Debt 2025 * | 17.76M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.67
x | P/E ratio 2025 * |
-0.72
x | Employees | 19 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.75% |
More Fundamentals
* Assessed data
More news
Latest transcript on Unity Biotechnology, Inc.
More recommendations
More press releases
| 1 day | -4.38% | ||
| 1 week | -4.97% | ||
| Current month | -0.65% | ||
| 1 month | +1.32% | ||
| 3 months | -14.53% | ||
| 6 months | -15.00% | ||
| Current year | -20.73% |
1 week
1.52
1.67
1 month
1.461.67
Current year
1.462.02
1 year
1.463.82
3 years
1.4650.85
5 years
1.46154.40
10 years
1.46245.60
| Managers | Title | Age | Since |
|---|---|---|---|
Anirvan Ghosh
CEO | Chief Executive Officer | 60 | 20-03-29 |
| Founder | 56 | 09-03-29 | |
Lynne Sullivan
DFI | Director of Finance/CFO | 58 | 20-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul Berns
BRD | Director/Board Member | 57 | 18-03-26 |
| Director/Board Member | 52 | 15-02-28 | |
Keith Leonard
CHM | Chairman | 62 | 15-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 1.53 | -4.38% | 63,213 |
| 24-05-09 | 1.6 | -1.84% | 15,784 |
| 24-05-08 | 1.63 | +0.62% | 17,172 |
| 24-05-07 | 1.62 | +1.25% | 45,768 |
| 24-05-06 | 1.6 | -0.62% | 39,631 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotes
Unity Biotechnology, Inc. is a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. It is targeting specific biological mechanisms implicated in diseases of aging. Its core therapeutic approach targets cellular senescence and is advancing senolytic programs primarily in ophthalmologic disorders. In addition, it has other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/VEGF bispecific to treat vascular eye disease. UBX1325 is its advanced lead drug candidate for age-related diseases of the eye, including diabetic macular edema. UBX1967 is its back-up compound to UBX1325. UBX2089, an α-Klotho hormone drug candidate, which is being researched for multiple neurology indications.
Calendar
2024-08-05
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.53
USD
Average target price
6
USD
Spread / Average Target
+292.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.73% | 25.68M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- UBX Stock
